Navigation Links
Sirion Therapeutics Announces Positive Phase III Results for Difluprednate
Date:10/25/2007

- Data Support NDA Submission -

TAMPA, Fla., Oct. 25 /PRNewswire-FirstCall/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced positive preliminary results from its Phase III difluprednate (ST-601) program, which evaluated the steroid's potential to rapidly resolve inflammation in the eye following ocular surgery.

"We are very pleased with the data that demonstrate difluprednate's potential as a potent, well-tolerated steroid treatment for post-operative inflammation," said Dr. Roger Vogel, Sirion's Chief Medical Officer. "Based on these data, Sirion is moving forward with its plans to submit a New Drug Application to the FDA."

The Phase III program consisted of two multi-center, randomized, double- masked studies that compared the safety and efficacy of difluprednate 0.05% to placebo, dosed two (BID) or four (QID) times daily beginning 24 hours after surgery. The studies included 439 subjects who presented with Grade 2 (an inflammatory cell count greater than or equal to 10) or higher the day after surgery. Inflammation was measured by the number of cells in the anterior chamber of the eye with a Grade 0 equaling less than or equal to one cell. The primary efficacy endpoint measured the proportion of subjects whose inflammation reached Grade 0 at Day 8.

Both difluprednate dosing regimens were superior to placebo at the primary endpoint, reaching high statistical significance at Day 8 and maintaining superiority through both the treatment period (Day 15) and the tapering period (Day 29). At Day 15, 56% of subjects on the BID regimen reached Grade 0 compared to 16% in the control group (p<0.0001). Of the subjects on the QID regimen, 63% reached Grade 0 at Day 15. This was also statistically significant when compared to placebo, but not clinically different than the BID regimen. In addition, both difluprednate groups were statistically better than placebo in eliminati
'/>"/>

SOURCE Sirion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Sirion Therapeutics Announces Clinical Data to be Presented at the 2007 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic ... . (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... policy support, China,s orthopedic instrument ... total market size rising from 3.28 billion yuan in ...
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced ... older adults suffering from the severe cold weather that has ... committed to helping those in need; so to support these ... contributions up to $250,000, which could mean up to $500,000 ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) announces ... condition to the announced tender offer for all of the outstanding ... result of the waiver, the transaction is no longer conditional on ... January 24, 2014 following the currently scheduled expiration time, subject to ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... YORK, Feb. 15, 2012 Delcath Systems, Inc. (NASDAQ: ... ( Instituto Europeo di Oncologia – IEO) introduced ... a Feb. 15 press conference and discussed the status ... CHEMOSAT is a critical new treatment option for patients ...
... ERT (NASDAQ: ERT ) announced today that it ... year 2011 Monday, February 27, after the market closes. After ... 5:00 PM ET that day. For the conference ... United States or 1-412-858-4600 when calling internationally. There will be ...
Cached Medicine Technology:Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 2Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 3Delcath CHEMOSAT Presented as Innovative Treatment for Liver Metastases by European Institute of Oncology 4ERT to Report Fourth Quarter and Full Year 2011 Operating Results 2
(Date:4/24/2014)... Ill. It is better to give than to receive ... giving, a new study suggests. , The study found that ... as giving their money to family members, are less likely ... from taking risks or keeping the money for themselves. , ... the National Academy of Sciences . , The study focused ...
(Date:4/24/2014)... Ore. An Oregon State University researcher has found ... of the symptoms of autism spectrum disorder in very ... be the first to show a direct relationship between ... fine and gross motor skills should be included in ... MacDonald, an assistant professor in OSU,s College of Public ...
(Date:4/24/2014)... University of York reveals that a process that forms ... system may also play a pivotal role in the ... by Dr Will Brackenbury, a Medical Research Council Fellow ... how voltage-gated sodium channels assist in the metastasis of ... of excitable cells, such as neurons, where they are ...
(Date:4/23/2014)... 2014 Pregnant immigrants from Sub-Saharan Africa, Latin ... during pregnancy, according to new research from St. ... the British Journal of Obstetrics and Gynaecology ... rates among immigrants and native-born women in six ... Sweden, Spain (Catalonia and Valencia) and the United ...
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2
... , AUDUBON, Pa., June 2 Globus Medical, Inc., the ... announced the launch of the COALITION(TM) ACDF Spacer System. ... provide the biomechanical strength of a traditional ACDF with less ... , The COALITION(TM) technology combines a PEEK interbody ...
... June 2 Cordex Pharma, Inc. (OTC Bulletin Board: ... Administration (FDA) has approved the design of pivotal, Phase ... an antiarrhytmic drug for the acute treatment of patients ... Assessment (SPA) process. , , ATPace(TM) is ...
... iMedica Corporation , a leading developer ... participation in the American College of Physicians ... Designed to assist physicians in choosing the best EHR for ... standards. The EPP provides detailed information to ACP members who ...
... Planned Spinoff of CareFusion Corporation , , DUBLIN, Ohio, ... and services that improve the safety and productivity of health ... quarterly dividend to $0.175 per share, or $0.70 per share ... announcement is particularly meaningful in that it comes in advance ...
... Medical, Inc. (Nasdaq: SLTM ), a global leader ... present at the Eight Annual Needham Life Sciences Conference at ... scheduled for 9:30 a.m. Eastern Time on Thursday, June 11, ... Officer, will review the company,s business strategy and recent corporate ...
... if you can find one , , BALTIMORE, June 2 ... late February, the Centers for Disease Control (CDC) says there are ... time of year. According to health officials, it is not too ... , Those who are in higher risk groups should receive ...
Cached Medicine News:Health News:Globus Medical Announces Launch of COALITION(TM) ACDF Spacer System 2Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 2Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 3Health News:Cordex Receives Special Protocol Assessment Approval from FDA for ATPace(TM) 4Health News:iMedica Participates in American College of Physicians' EHR Partners Program 2Health News:iMedica Participates in American College of Physicians' EHR Partners Program 3Health News:Cardinal Health Increases Quarterly Dividend By 25 Percent 2Health News:Cardinal Health Increases Quarterly Dividend By 25 Percent 3Health News:Cardinal Health Increases Quarterly Dividend By 25 Percent 4Health News:Solta Medical, Inc. to Present at 8th Annual Needham Life Sciences Conference 2Health News:Seasonal Flu Lingers 2
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: